|Tesidolumab is a fully human monoclonal antibody targeting complement C5. Like eculizumab, this investigational monoclonal inhibits terminal complement activation.
Peptide sequence and secondary structural information for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence alignment analysis using the heavy and light variable domains of tesidolumab provide 100% matches to SEQ ID NOs 7 and 8 respectively from patent US8241628 . These peptide sequences correspond to antibody (MOR0)8109 in said patent.